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Abstract 
The utility of routine chimerism analysis as a prognostic indicator of subsequent outcomes after 
allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning regimens 
remains controversial. To address this controversy, routine chimerism test results at 2 – 6 
months after HCT with myeloablative conditioning regimens were evaluated for association with 
subsequent risks of chronic graft versus host disease (GVHD), non-relapse mortality (NRM), 
relapse and overall mortality. Only 70 (5%) of 1304 patients had <95% donor-derived cells in 
the marrow. Low donor chimerism in the marrow occurred predominantly among patients with 
low risk disease as compared to higher risk diseases and was significantly associated with a 
reduced risk of chronic GVHD. Among 673 patients tested, 164 (24%) had <85% donor-derived 
T cells in the blood. Low donor T cell chimerism occurred predominantly among patients with 
low risk disease as compared to higher risk diseases, among those who had conditioning with 
busulfan as compared to TBI, and among those with lower grades of acute GVHD. Low donor T 
cell chimerism in the blood was significantly associated with a reduced risk of chronic GVHD, 
but not with the risks of relapse, NRM or overall mortality. Routine testing of chimerism in the 
marrow and blood at 2 – 6 months after HCT with myeloablative conditioning regimens may be 
helpful in documenting engraftment in clinical trials but provides only limited prognostic 
information in clinical practice.  
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Introduction 
Chimerism testing can be used to document engraftment after allogeneic hematopoietic cell 
transplantation (HCT) and can be highly useful in the diagnosis of rejection and recurrent 
malignancy. Lineage–specific analysis increases the sensitivity of the method and may provide 
more specific information [1,2]. Chimerism tests demonstrating the persistence of recipient cells 
after HCT with non-myeloablative regimens can also predict an increased risk of rejection or 
recurrent malignancy, but the role of chimerism analysis as a prognostic indicator of subsequent 
transplant outcomes after HCT with myeloablative conditioning regimens remains controversial. 
While Lamba et al. [3] reported higher relapse rates and lower overall survival (OS) in patients 
with mixed chimerism (MC) on day 90 after HCT, Doney et al. [4] found no correlation between 
persistence of recipient cells at 2 – 3 months after HCT and subsequent outcomes in patients 
who had myeloablative conditioning regimens. The results of Doney et al. are consistent with 
consensus recommendations that documentation of chimerism is not essential after HCT with 
myeloablative conditioning regimens and conventional GVHD prophylaxis [1].  
In order to address this controversy, we reviewed results of routine chimerism tests at 2 – 6 
months after HCT with myeloablative conditioning regimens in a large cohort of patients in order 
to evaluate whether test results were associated with subsequent risks of chronic graft versus 
host disease (GVHD), non relapse mortality (NRM), recurrent malignancy and survival.   
 
Methods 
The cohort included all patients who had a first allogeneic HCT with the use of a myeloablative 
conditioning regimen at the Fred Hutchinson Cancer Research Center, and had routine 
chimerism testing of the marrow (n = 1304) (Table 1) or both granulocytes and T cells in the 
blood (n = 673) (Table 2) with the use of sex markers or molecular markers as part of the 
departure evaluation before their care was transferred from the transplant center to the referring 
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physician. Routine testing was done on a single occasion, and the choice of samples to be 
tested was dictated by institutional practices, which changed over time. Transplant for patients 
who had testing of the marrow were done between July 1988 and September 2006. Transplants 
for patients who had testing of blood cells were done between September 2000 and September 
2006. Testing was done at a median of 79 (range, 53-188) days after HCT. Patients were 
excluded from further analysis if the departure testing showed evidence of recurrent 
malignancy. All patients included for consideration signed IRB-approved informed consent 
documents allowing medical information to be reviewed for research purposes, and the IRB 
approved the use of medical information for this retrospective study.   
Blood cells were sorted according to expression of CD33 and CD3 by flow-cytometry before 
chimerism testing. Non-fractionated aspirated marrow and fractionated blood cells from patients 
with sex-mismatched donors were tested by fluorescent in situ hybridization with Y 
chromosome-specific probes or with both Y and X-chromosome-specific probes [5]. Beginning 
in 1998, DNA samples from patients with same-sex donors were tested by amplification and 
semi-quantitative analysis of variable number tandem repeat loci with informative 
polymorphisms. Amplified products were analyzed semi-quantitatively after electrophoresis and 
silver staining in polyacrylamide gels [6]. As assessed by mixing experiments, this method has 
between 0.1 – 5% sensitivity, depending on the relative size of the informative markers. 
Beginning in 2004, samples from patients with same-sex donors were tested by multiplex 
amplification of short tandem repeat loci with informative polymorphisms (PowerPlex 16; 
Promega, Madison, WI, USA). Amplified products were analyzed quantitatively by capillary 
electrophoresis (ABI 3130 x 1; Applied Biosystems, Foster City, CA, USA). This method has at 
least 0.5% sensitivity, as assessed by mixing experiments [7]. Pretransplant samples from the 
donor and recipient were routinely included as controls.  
Survival probabilities were estimated according to the Kaplan-Meier method. Probabilities of 
recurrent malignancy, NRM and chronic GVHD were estimated by the cumulative incidence 
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method. Follow-up for survival and recurrent malignancy was censored at the date of last 
contact or death. Follow-up for NRM and chronic GVHD was censored at the onset of recurrent 
malignancy or date of last contact, whichever occurred first. Chi-square test or Fisher’s exact 
test was used to estimate the statistical significance of categorical differences. Cox proportional 
hazards analysis was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for 
mortality, recurrent malignancy, NRM and chronic GVHD for patients with low donor chimerism 
compared to those without low donor chimerism. Adjustment factors considered were disease 
risk (low risk included chronic myeloid leukemia in chronic phase and refractory anemia; high 
risk included malignant disease in relapse, refractory anemia with excess blasts in 
transformation, and chronic myeloid leukemia in blast crisis; intermediate risk included all other 
diagnoses), conditioning (busulfan and cyclophosphamide, cyclophosphamide and total body 
irradiation, and all other regimens), grafting with growth factor-mobilized blood cells, and grades 
II – IV acute GVHD with onset before chimerism testing.     
 
Results 
Two factors were considered in defining a threshold for “low donor chimerism.” First, the 
threshold percentage of recipient cells had to be above the lower limit of sensitivity in reliably 
detecting these cells by the assays used for testing (5%) in order to avoid confounding caused 
by false-negative results. Second, the number of patients with low donor chimerism had to be 
high enough to allow reasonable statistical power for observing associations with clinical 
outcomes, if possible. Routine testing of aspirated marrow at 2 – 6 months after HCT showed 
>5% recipient cells (<95% donor cells) in only 70 (5%) of the 1304 patients tested (Table 1). 
Although this threshold does not provide optimal statistical power, the use of a less stringent 
definition of low donor chimerism was not feasible because of limits in the sensitivity of 
chimerism tests.       
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Low donor chimerism (<95% donor cells) in the marrow occurred more frequently among 
patients with low-risk diseases (predominantly chronic myeloid leukemia) as compared to 
higher–risk diseases (predominantly acute leukemia) (P < .001). Persistence of >5% recipient 
cells was not significantly associated with donor-recipient gender combination, relationship 
between the donor and recipient, the conditioning regimen, the use of growth factor mobilized 
blood versus marrow, the post-transplant immunosuppressive regimen or the severity of acute 
GVHD (Table 1). Correlation with clinical outcome showed a statistically significant association 
of low donor chimerism in the marrow with decreased subsequent risk of chronic GVHD (HR, 
0.65; 95% C.I., 0.5 – 0.9; P = .02) but not with subsequent risks of recurrent malignancy, non-
relapse mortality or overall mortality (Table 3, Figure 1).     
Based on the same considerations used to define low donor chimerism in the marrow, the 
presence of <95% donor-derived cells was used to define low donor chimerism in blood 
granulocytes. Only 14 (2%) of 673 patients had <95% donor-derived granulocytes in the blood. 
Low donor chimerism in blood granulocytes occurred too infrequently for meaningful analysis of 
correlation with transplant characteristics or clinical outcome (Tables 2 and 3). The percentile 
distribution of T cell chimerism suggested that the presence of <85% donor-derived cells could 
be used to define low donor chimerism (Figure 2). By this definition, low donor chimerism 
(<85%) was observed in 164 (24%) of the 673 patients (Table 2). Low T cell chimerism occurred 
more frequently among patients with chronic myeloid leukemia or myelodysplastic syndrome as 
compared to acute lymphoid leukemia (P < .001), among patients with low-risk diseases as 
compared to high-risk diseases (P < .001), among patients who had conditioning with busulfan 
as compared to TBI (P < .001) and among patients with grades 0 – 1 acute GVHD as compared 
to grades III – IV GVHD (P < .001). Low T cell chimerism occurred less frequently when the 
donor and recipient were HLA-mismatched (P < .001) and also among patients who received a 
combination of calcineurin inhibitor with mycophenolate mofetil as compared to methotrexate 
after the transplant (P = .003). Low T cell chimerism was not significantly associated with donor 
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recipient gender combination, the relationship between the donor and recipient, or the source of 
stem cells (Table 2). 
Correlation with clinical outcome showed a statistically significant association between low T 
cell chimerism and a reduced subsequent risk of chronic GVHD (HR, 0.76; 95% C.I., 0.6 – 1.0; 
P = .02) (Table 3 and Figure 3).  This association was slightly attenuated after adjustment for 
differences in pretransplant risk category, conditioning regimen, use of mobilized blood cells, 
and prior grades II – IV GVHD (HR, 0.80; 95% C.I., 0.6 – 1.0, P = .09).  In univariate analysis, 
low T cell chimerism was significantly associated with lower overall mortality (HR, 0.66; 95% C.I. 
0.5 – 0.9; P = .02) (Table 3, Figure 3), but after adjustment for differences in disease risk group 
and conditioning regimen, this association was no longer statistically significant (HR, 0.77; 95% 
C.I. 0.5 – 1.1; P = .16).  Low T cell chimerism showed a trend for association with a lower risk of 
NRM (HR, 0.62; 95% C.I. 0.4 – 1.0; P = .07) but not with an increased risk of recurrent 
malignancy (Table 3).   
To some extent, the association of low donor chimerism in the marrow with a reduced risk of 
chronic GVHD could reflect low donor T cell chimerism in the blood, since aspirated marrow 
contains an appreciable number of T cells from the blood. To test this hypothesis, we evaluated 
the correlation between donor chimerism levels in the marrow and the blood in 173 patients who 
had both tests. Low donor marrow chimerism was observed in 6 of 47 (12.8%) patients with low 
T cell chimerism, compared to 3 of 126 (2.4%) patients with high donor T cell chimerism (P  = 
.01, Fisher’s exact test). Among these patients, low donor T cell chimerism was significantly 
associated with a reduced risk of chronic GVHD (HR, 0.51; 95% C.I., 0.3 – 0.9; P = .02), but low 
donor marrow chimerism was not (HR, 0.97; 95% C.I. 0.4 – 2.7; P = .96).  
None of the 509 patients with ≥ 85% donor T cell chimerism had a second transplant for 
treatment of graft failure, and only 2 of the 164 (1.2%) patients with low donor T cell chimerism 
had a second transplant because of poor graft function. In one case, the results on day 81 after 
the first transplant showed 5 – 15% donor-derived T cells in the blood with 95 – 99% donor-
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derived granulocytes, and results on day 160 showed 1 – 5% donor-derived T cells in the blood 
again with 95 – 99% donor-derived granulocytes. In the other case, the results on day 81 after 
the first transplant showed 60% donor-derived T cells in the blood with 77% donor-derived 
granulocytes, and results on day 111 were similar.       
 
Discussion 
In this study, we found that at 2 – 6 months after HCT with myeloablative conditioning regimens, 
only a small minority of patients had less than 95% donor-derived cells in the marrow and in 
blood granulocytes. Low donor chimerism in the marrow occurred predominantly among 
patients with low-risk diseases such as chronic phase CML and was associated with a reduced 
risk of chronic GVHD.  Approximately 25% of the patients in this study had < 85% donor-derived 
T cells in the blood at 2 – 6 months after HCT with myeloablative conditioning regimens.  Low 
donor chimerism in blood T cells occurred predominantly among patients with low-risk diseases 
and was associated with the absence of TBI in the conditioning regimen and the absence of 
acute GVHD. Low donor chimerism in the marrow and in blood T cells at 2 – 6 months after 
HCT with myeloablative conditioning regimens was significantly associated with a reduced risk 
of chronic GVHD but not with the risks of recurrent malignancy, non-relapse mortality, overall 
mortality, or graft failure leading to a second transplant. Routine testing of chimerism in the 
marrow and blood at 2 – 6 months after HCT with myeloablative conditioning regimens may be 
helpful in documenting engraftment in clinical trials but provides only limited prognostic 
information in clinical practice.   
The threshold of < 85% donor-derived T cells used to define low donor chimerism in our 
study was selected empirically and may differ from the values used in other studies. The 
percentile distribution of T cell chimerism in our study showed a smooth progression from low 
values to high values, with no obvious break point. The 85% threshold approximates the 
inflection of the curve and had no a priori biological significance. 
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The absence of prior myelosuppressive treatment before referral for HCT most likely 
accounts for the association of low-risk diseases with low donor marrow chimerism and low 
donor T cell chimerism at 2 – 6 months after HCT with myeloablative conditioning regimens. 
Low risk diseases included chronic myeloid leukemia in chronic phase and refractory anemia, 
which are almost never treated with high-dose myelosuppressive treatment. High risk diseases 
included malignant disease in relapse, refractory anemia with excess blasts in transformation, 
and chronic myeloid leukemia in blast crisis, and intermediate risk diseases included all other 
diagnoses. We acknowledge that some patients in the intermediate risk and high risk categories 
did not receive prior myelosuppressive treatment. We used the low and higher-risk categories 
as a surrogate for the respective absence or presence of prior myelosuppressive treatment, 
although we do not have direct data demonstrating this correlation. A similar explanation has 
been invoked for the observation that the incidence of graft rejection after HCT with 
nonmyeloablative conditioning regimens is higher among patients with low-risk diseases than 
among those with higher-risk diseases [8]. These results support the hypothesis that previous 
exposure to multiple cycles of myelosuppressive chemotherapy increases the susceptibility of 
recipient hematopoietic cells and T cells to the effects of both myeloablative and 
nonmyeloablative pretransplant conditioning regimens.   
The observation that low donor T cell chimerism occurred more frequently than low donor 
myeloid chimerism suggests that prior myelosuppressive treatment, the pretransplant 
conditioning regimen and the effects of acute GVHD have a greater cumulative effect on 
myeloid cells than on T cells in the recipient. Mattsson et al. [9] reported similar lower levels of T 
cell chimerism compared to myeloid chimerism. The results of chimerism testing at 2 – 6 
months after HCT suggest that the fractionated TBI exposures and doses of busulfan used in 
this study had equivalent cumulative effects on recipient myeloid cell but different effects on 
recipient T cells. These results indicate that fractionated TBI has a more potent 
immunosuppressive effect than busulfan, as demonstrated by other studies [9]. The association 
 9
of HLA-mismatching and acute GVHD with decreased proportions of persisting recipient T cells 
and higher levels of donor T cell chimerism is consistent with the hypothesis that the targets of 
acute GVHD include recipient T cells, as well as basal epithelial cells in the skin, bile duct 
epithelial cells in the liver, and crypt epithelial cells in the gastrointestinal tract.   
Our results demonstrating that persistence of recipient cells in the marrow or blood T cells 
beyond 2 months after HCT is associated with a reduced risk of chronic GVHD after allogeneic 
HCT with myeloablative conditioning regimens are consistent with results of other studies. 
McCann et al. [10] showed that patients with mixed chimerism had a decreased risk of chronic 
GVHD after HCT for treatment of aplastic anemia, while Balon et al. [11] showed that 
development of complete chimerism within the first 3 months after HCT was associated with an 
increased risk of chronic GVHD. To some extent, low donor chimerism in aspirated marrow 
specimens could be explained by low T cell chimerism in the blood. The reduced risk of chronic 
GVHD associated with low donor chimerism in the blood and not with low donor chimerism in 
the marrow among patients who had both tests suggests that low donor T cell chimerism (or 
persistence of recipient T cells) represents the dominant association. Recipient T cells could 
have suppressive or veto effects on donor cells that cause chronic GVHD, thereby inducing a 
state of tolerance. Alternatively, the association of high donor T cell chimerism with an 
increased risk of chronic GVHD could reflect the activity of some other factor that 
simultaneously eliminates recipient T cells and also induces chronic GVHD.  
The absence of a correlation between low donor T cell chimerism and the subsequent risk of 
recurrent malignancy is somewhat unexpected, since persistence of recipient T cells was 
associated with a decreased risk of chronic GVHD and since development of chronic GVHD has 
been associated with a decreased risk of recurrent malignancy. Any increment in risk of 
recurrent malignancy associated with the observed decrease in risk of chronic GVHD among 
patients with persisting recipient T cells could have been too small to measure in a cohort of 
patients with a variety of malignant diseases. The absence of a correlation between low donor 
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marrow chimerism or low donor T cell chimerism and the subsequent risk of recurrent 
malignancy in our study is consistent with results of several previous studies [4,12,13,14]. Other 
studies, however, have shown that persistence of recipient myeloid cells [15,16] or T cells [17] 
after unmanipulated [15,16] or T cell-depleted [16,17] HCT was associated with an increased 
risk of recurrent malignancy among patients with CML. Associations between persistence of 
recipient cells and an increased risk of recurrent malignancy have also been reported among 
patients with acute leukemia [3,18]. Chimerism assays can certainly be used as a diagnostic 
indicator of recurrent malignancy, but their utility as a prognostic indicator of recurrent 
malignancy depends on the nature of the malignancy, the intensity of the conditioning regimen 
[8] and the methods used to prevent GVHD.      
Contrary to results of Lamba et al. [3], our data do not support an association between 
survival and low donor T cell chimerism at 2 – 6 months after HCT with myeloablative 
conditioning. On the other hand, we observed a trend for an association of low donor T cell 
chimerism with a reduced subsequent risk of non-relapse mortality. This association is at least 
partly explained by the reduced risk of chronic GVHD associated with persistence of recipient T 
cells, since chronic GVHD is the primary cause of late non-relapse mortality after allogeneic 
HCT.    
Our current results do not support an association between low donor T cell chimerism and a 
subsequent risk of graft failure after T cell-replete HCT with myeloablative conditioning 
regimens, although other studies have shown such associations [2]. Although graft rejection can 
be caused by recipient T cells surviving the conditioning regimen, the presence of a particular 
cell population does not allow direct inferences concerning its function capabilities [19]. Hence, 
our results emphasize that the persistence of recipient T cells after HCT does not necessarily 
indicate that rejection is likely to occur. Chimerism assays can certainly be used as a diagnostic 
indicator of rejection, but their utility as a prognostic indicator of rejection depends on other 
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factors that affect the risk of rejection, such as the intensity of the conditioning regimen and the 
use of T cell depletion to prevent GVHD. 
To some extent, the association between donor T cell chimerism and the subsequent risk of 
chronic GVHD could be used in making decisions about the withdrawal of immunosuppressive 
treatment or enrolment of patients in clinical trials testing new approaches for prevention of 
chronic GVHD. Routine chimerism testing at 2 – 6 months after HCT with myeloablative 
conditioning regimens can also be used to document engraftment in clinical trials. Our results 
showing the absence of strong correlations with risks of recurrent malignancy, non-relapse 
mortality and overall survival apply only for chimerism testing in patients who have had HCT 
with myeloablative conditioning regimens and should not be extrapolated to patients who have 
had non-myeloablative conditioning regimens [8]. Although our results apply to the use of 
routine chimerism testing for prognostic purposes, they have no relevance regarding the use of 
chimerism tests for diagnostic purposes. 
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Table 1. Characteristics of patients who had testing of marrow cells  
 
Characteristic 
Entire                
Cohort 
<95% Donor             
Marrow Cells 
Number of patients (%) 1304 70 (5) 
Patient age, median (range), y 37 (0-66) 41 (0-63) 
Disease at transplantation, no. (%)   
Myelodysplastic syndrome 195 10 (5) 
Acute myeloid leukemia 300  3 (1) 
Chronic myeloid leukemia 443                  40 (9) 
Acute lymphoid leukemia 182  4 (2) 
Non-Hodgkin lymphoma or Hodgkin disease 68  5 (7) 
Other                  116  8 (7) 
Pretransplant risk category, no. (%)   
Low 415 37 (9) 
Intermediate 628 25 (4) 
High 261  8 (3) 
Donor age, median (range), y 37 (0-81) 40 (1-65) 
Donor/recipient sex, no. (%)*   
Male/male 286 10 (4) 
Male/female 411 28 (7) 
Female/male 457 20 (4) 
Female/female 148 12 (8) 
Donor type, no. (%)   
HLA-identical related 649 38 (6) 
HLA-mismatched related 108  8 (7) 
HLA-matched unrelated 293                  13 (4) 
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HLA-mismatched unrelated 254 11 (4) 
Conditioning regimen, no. (%)   
Cyclophosphamide and TBI 676 26 (4) 
Busulfan and cyclophosphamide 375 27 (7) 
Busulfan and TBI 43 1 (2) 
Busulfan, cyclophosphamide, and TBI 59 1 (2) 
Busulfan, cyclophosphamide, and ATG 27  4 (15) 
Cyclophosphamide, TBI, and ATG 41 3 (7) 
Other containing ATG  55 4 (7) 
Other 28  4 (14) 
Source of stem cells, no. (%)   
Bone marrow 1012 57 (6) 
Mobilized blood 279 10 (4) 
Cord blood 13   3 (23) 
GVHD prophylaxis, no. (%)   
Cyclosporine and methotrexate 1061 63 (6) 
Tacrolimus and methotrexate 92  4 (4) 
Methotrexate 31 0 
Calcineurin inhibitor 92  3 (3) 
Calcineurin inhibitor and MMF 21 0 
Other  7 0 
Prior acute GVHD, no. (%)†   
Grade 0 – I 292 20 (7) 
Grade II 742 36 (5) 
Grades III – IV  269 14 (5) 
* 2 patients received cord blood transplants from 2 donors, one male and the other female.  
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† GVHD could not be graded in one patient because of severe regimen-related toxicity. 
Table 2. Characteristics of patients who had testing of blood cells  
 
Characteristic 
Entire         
Cohort         
<95% Donor     
Granulocytes  
<85% 
Donor T 
Cells  
Number of patients (%) 673 14 (2) 164 (24) 
Patient age, median (range), y 39 (0-66) 34 (1-57) 42 (1-64) 
Disease at transplantation, no. (%)    
Myelodysplastic syndrome 164 3 (2) 57 (35) 
Acute myeloid leukemia 216 4 (2) 36 (17) 
Chronic myeloid leukemia 118 3 (3) 52 (44) 
Acute lymphoid leukemia 111 0 3 (3) 
Other 64 4 (6) 16 (25) 
Pretransplant risk category, no. (%)    
Low 144 4 (3) 55 (38) 
Intermediate 434 8 (2) 98 (23) 
High 95 2 (2) 11 (12) 
Donor age, median (range), y 38 (1-76) 30 (1-60) 38 (5-65) 
Donor/recipient sex, no. (%)*    
Male/male 204 5 (2) 50 (25) 
Male/female 155 3 (2) 42 (27) 
Female/male 160 2 (1) 39 (24) 
Female/female 153 4 (3) 33 (22) 
Donor type, no. (%)    
HLA-identical related 288 10 (3) 79 (27) 
HLA-mismatched related 15 0  2 (13) 
HLA-matched unrelated 225 3 (1) 63 (28) 
HLA-mismatched unrelated 145 1 (1) 20 (14) 
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Conditioning regimen, no. (%)    
Cyclophosphamide and TBI 250 2 (1) 13 (5) 
Busulfan and cyclophosphamide 287 6 (2) 106 (37) 
Busulfan, cyclophosphamide, and ATG 42 2 (5)   6 (14) 
Cyclophosphamide, TBI, and ATG 25 0   3 (12) 
Other containing ATG  35 2 (6) 20 (57) 
Other 34 1 (3) 16 (47) 
Source of stem cells, no. (%)    
Bone marrow 195 6 (3) 62 (32) 
Mobilized blood 460 7 (2) 101 (22) 
Cord blood 18 1 (6)  1 (6) 
GVHD prophylaxis, no. (%)    
Cyclosporine plus methotrexate 437 10 (2) 120 (27) 
Tacrolimus plus methotrexate 157 3 (2) 37 (24) 
Methotrexate 3 0 0 
Calcineurin inhibitor 43 1 (2)   6 (14) 
Calcineurin inhibitor and MMF 33 0 1 (3) 
Prior acute GVHD, no. (%)    
Grade 0 – I 157 5 (3) 56 (36) 
Grade II 426 8 (2) 96 (23) 
Grades III – IV  90 1 (1) 12 (13) 
* 1 patient received a cord blood transplant from 2 donors, one male and the other female. 
Table 3.  Association of low donor chimerism with subsequent outcomes after HCT 
 Overall Mortality  Relapse  Non-relapse Mortality Chronic GVHD 
 HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P 
Donor chimerism in marrow 
  ≥95% (n=1234) 1.0 1.0 1.0 1.0 
  <95% (n=70) 0.97 (0.7-1.4) 
 
.87 1.35 (0.9-2.1) 
 
.17 0.97 (0.6-1.7) 
 
.90 0.65 (0.5-0.9) 
 
.02 
Donor chimerism in blood granulocytes 
  ≥95% (n=659) 1.0 1.0 1.0 1.0 
  <95% (n=14) 0.60 (0.2-1.9) 
 
.38 0.59 (0.1-2.4) 
 
.45 0.90 (0.2-3.6) 
 
.88 0.67 (0.3-1.4) 
 
.30 
Donor chimerism in blood T cells 
  ≥85% (n=509) 1.0 1.0 1.0 1.0 
  <85% (n=164) 0.66 (0.5-0.9) 
 
.02 0.84 (0.6-1.2) 
 
.38 0.62 (0.4-1.0) 
 
.07 0.76 (0.6-1.0) 
 
.02 
*Results do not reflect adjustment for other risk factors.  
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Figure Legends 
 
 
Figure 1.  Clinical outcomes according to level of donor chimerism in the marrow.    
 
Figure 2.  Percentile distribution of donor T cell chimerism in the blood.   
 
Figure 3.  Clinical outcomes according to level of donor T cell (CD3) chimerism in the 
blood.    
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Figure 3 Figure 3
